Spark Therapeutics, Inc.
Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | |
|---|---|---|---|---|---|---|
| Revenue | $15.7M | $1.3M | $20.2M | $22.1M | $633,932 | $0 |
| Operating income | −$48.9M | −$52.9M | −$125.4M | −$47.3M | −$24.3M | −$57.3M |
| Net income | −$46.4M | −$52.3M | −$123.7M | −$47.1M | −$24.3M | −$57.3M |
| Total assets | $814.4M | $616.8M | $373.9M | $329.8M | $90.4M | — |
| Total liabilities | $317.8M | $103.2M | $43.6M | $39.2M | $35.2M | — |
| Equity | $496.5M | $513.6M | $330.3M | $290.5M | $55.2M | — |
| EPS (diluted) | $-1.25 | — | — | — | — | — |
| Shares out. | 37.2M | 31.0M | 27.1M | 27.1M | 6.3M | — |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2018- Operating margin
- −312.0%
- Net margin
- −295.8%
- Return on equity
- −9.3%
- Return on assets
- −5.7%
- Return on capital (ROCE)
- −6.5%
- Liabilities / assets
- 39.0%
- Debt / equity
- 0.64×
- Book value / share
- $13.34
- Revenue growth (YoY)
- 1130.5%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2018- Altman Z″ (distress)
- 2.94safe
- Accruals / assets
- 3.0%clean
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 warning● 4 good- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Active Not Recruitingreadout ~2015-07Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis
- Phase 2Recruitingreadout ~2026-05-30SB17170 Phase 2 Trial in IPF Patients
- Phase 1Recruitingreadout ~2027-06-30SB17170 Phase 1 Clinical Trial in Solid Tumors
- Phase 1/2Active Not Recruitingreadout ~2027-10Phase 1 Follow-on Study of AAV2-hRPE65v2 Vector in Subjects With Leber Congenital Amaurosis (LCA) 2
- Phase 1/2Active Not Recruitingreadout ~2032-04A Gene Transfer Study for Late-Onset Pompe Disease (RESOLUTE)
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.